Siyu Tian

机构：North China Electric Power University, Chinese Academy of Sciences, Sinovac Biotech, Indus Biotech (India), Institute of Microbiology, University of Chinese Academy of Sciences · ORCID：0000-0002-1892-1305

发表论文 20 篇 · 总被引 822 次 · h-index 7

代表论文

• Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials (2021 · The Lancet Infectious Diseases · 被引 456)
• Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2 (2020 · Cell Discovery · 被引 194)
• A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2 (2021 · Nature Communications · 被引 81)
• Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials (2020 · medRxiv · 被引 23)
• Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice (2021 · Cell Discovery · 被引 17)
• A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates (2024 · Frontiers in Immunology · 被引 13)